ES2614923T3 - Combinación de antibióticos para tratar una enfermedad autoinmune - Google Patents
Combinación de antibióticos para tratar una enfermedad autoinmune Download PDFInfo
- Publication number
- ES2614923T3 ES2614923T3 ES12834382.9T ES12834382T ES2614923T3 ES 2614923 T3 ES2614923 T3 ES 2614923T3 ES 12834382 T ES12834382 T ES 12834382T ES 2614923 T3 ES2614923 T3 ES 2614923T3
- Authority
- ES
- Spain
- Prior art keywords
- eae
- mice
- disease
- treatment
- vehicle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003115 biocidal effect Effects 0.000 title description 2
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract description 28
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 abstract description 7
- 229960004287 clofazimine Drugs 0.000 abstract description 7
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 abstract description 5
- 229960002626 clarithromycin Drugs 0.000 abstract description 5
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 abstract description 5
- 229960000885 rifabutin Drugs 0.000 abstract description 5
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 57
- 208000033068 episodic angioedema with eosinophilia Diseases 0.000 description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 201000010099 disease Diseases 0.000 description 27
- 239000002775 capsule Substances 0.000 description 18
- 238000002649 immunization Methods 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 9
- 208000016192 Demyelinating disease Diseases 0.000 description 8
- 206010012305 Demyelination Diseases 0.000 description 8
- 230000001640 apoptogenic effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 108010081690 Pertussis Toxin Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229960000556 fingolimod Drugs 0.000 description 3
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 101100398282 Mus musculus Kit gene Proteins 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 108010064578 myelin proteolipid protein (139-151) Proteins 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161536824P | 2011-09-20 | 2011-09-20 | |
| US201161536824P | 2011-09-20 | ||
| US201161537229P | 2011-09-21 | 2011-09-21 | |
| US201161537229P | 2011-09-21 | ||
| PCT/IB2012/002252 WO2013041963A2 (en) | 2011-09-20 | 2012-09-19 | A composition and method for treating an autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2614923T3 true ES2614923T3 (es) | 2017-06-02 |
Family
ID=47914967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12834382.9T Active ES2614923T3 (es) | 2011-09-20 | 2012-09-19 | Combinación de antibióticos para tratar una enfermedad autoinmune |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9901638B2 (enExample) |
| EP (1) | EP2758061B1 (enExample) |
| JP (1) | JP6035340B2 (enExample) |
| KR (1) | KR101987512B1 (enExample) |
| CN (1) | CN103813797B (enExample) |
| AU (1) | AU2012311235B2 (enExample) |
| BR (1) | BR112014006473A2 (enExample) |
| CA (1) | CA2849255C (enExample) |
| CL (1) | CL2014000671A1 (enExample) |
| DK (1) | DK2758061T3 (enExample) |
| ES (1) | ES2614923T3 (enExample) |
| HU (1) | HUE032959T2 (enExample) |
| IL (1) | IL231489A (enExample) |
| IN (1) | IN2014CN02908A (enExample) |
| MX (1) | MX347660B (enExample) |
| PL (1) | PL2758061T3 (enExample) |
| PT (1) | PT2758061T (enExample) |
| RU (1) | RU2621129C2 (enExample) |
| SG (1) | SG11201400386RA (enExample) |
| TW (1) | TWI573590B (enExample) |
| WO (1) | WO2013041963A2 (enExample) |
| ZA (1) | ZA201401954B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105307654B (zh) * | 2013-04-30 | 2022-06-07 | 托马斯·朱利叶斯·波洛迪 | 用于治疗微生物区系相关的精神病况和疾病的组合物和方法 |
| EP3145510B8 (en) * | 2014-05-22 | 2021-10-27 | Kuenstner, John, Todd | Treatment of diseases using combination of ultraviolet blood irradiation and antibiotics |
| BR112017008220A2 (pt) * | 2014-10-24 | 2018-01-09 | Redhill Biopharma Ltd. | terapia para inibição de replicação do vírus de rna de filamento único |
| AU2016336133B2 (en) * | 2015-10-06 | 2021-02-25 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
| CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN111148531A (zh) | 2017-09-08 | 2020-05-12 | 伊夫罗生物科学公司 | 细菌胞外囊泡 |
| CA3187031A1 (en) * | 2020-06-30 | 2022-01-06 | Redhill Biopharma Ltd. | Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections |
| EP4497437A4 (en) * | 2022-03-22 | 2025-03-12 | Kyoto University | MEDICINES FOR THE TREATMENT OR PREVENTION OF CHARCOT-MARIE-TOOTH DISEASE |
| CN116649295A (zh) * | 2023-03-20 | 2023-08-29 | 广西医科大学第一附属医院 | GluN1359-378多肽主动免疫PTZ诱发癫痫及认知障碍的动物模型、建立方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI0971735T1 (sl) * | 1997-04-01 | 2008-08-31 | Borody Thomas J | Postopek in sestavina za zdravljenje bolezni vnetja debelega äśrevesa |
| US7488580B1 (en) | 2005-03-10 | 2009-02-10 | University Of Central Florida Research Foundation, Inc. | Protocol for detection of Mycobacterium avium subspecies paratuberculosis in blood |
| US20090054380A1 (en) * | 2005-12-20 | 2009-02-26 | Greenstein Robert J | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection |
| US20080275063A1 (en) | 2007-04-24 | 2008-11-06 | Heike Schauerte | Inhibitors of protein kinases |
| WO2009042114A2 (en) * | 2007-09-21 | 2009-04-02 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
| CA2714043C (en) | 2008-02-08 | 2016-11-08 | Giaconda Limited | Methods and compositions for treating inflammatory bowel disease |
| WO2011011706A2 (en) * | 2009-07-24 | 2011-01-27 | The Johns Hopkins University | Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents |
-
2012
- 2012-09-18 TW TW101134166A patent/TWI573590B/zh not_active IP Right Cessation
- 2012-09-19 JP JP2014531331A patent/JP6035340B2/ja active Active
- 2012-09-19 HU HUE12834382A patent/HUE032959T2/hu unknown
- 2012-09-19 SG SG11201400386RA patent/SG11201400386RA/en unknown
- 2012-09-19 RU RU2014115807A patent/RU2621129C2/ru active
- 2012-09-19 PT PT128343829T patent/PT2758061T/pt unknown
- 2012-09-19 DK DK12834382.9T patent/DK2758061T3/en active
- 2012-09-19 CA CA2849255A patent/CA2849255C/en active Active
- 2012-09-19 MX MX2014003430A patent/MX347660B/es active IP Right Grant
- 2012-09-19 KR KR1020147010372A patent/KR101987512B1/ko not_active Expired - Fee Related
- 2012-09-19 IN IN2908CHN2014 patent/IN2014CN02908A/en unknown
- 2012-09-19 WO PCT/IB2012/002252 patent/WO2013041963A2/en not_active Ceased
- 2012-09-19 BR BR112014006473A patent/BR112014006473A2/pt not_active Application Discontinuation
- 2012-09-19 ES ES12834382.9T patent/ES2614923T3/es active Active
- 2012-09-19 AU AU2012311235A patent/AU2012311235B2/en not_active Ceased
- 2012-09-19 PL PL12834382T patent/PL2758061T3/pl unknown
- 2012-09-19 CN CN201280045735.5A patent/CN103813797B/zh active Active
- 2012-09-19 EP EP12834382.9A patent/EP2758061B1/en active Active
- 2012-09-19 US US14/345,839 patent/US9901638B2/en active Active
-
2014
- 2014-03-12 IL IL231489A patent/IL231489A/en active IP Right Grant
- 2014-03-17 ZA ZA2014/01954A patent/ZA201401954B/en unknown
- 2014-03-19 CL CL2014000671A patent/CL2014000671A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2279573T3 (es) | Terapia para el estreñimiento. | |
| Johnson et al. | Effects of Bifidobacterium infantis 35624 on post-inflammatory visceral hypersensitivity in the rat | |
| CA2849255C (en) | A composition and method for treating an autoimmune disease | |
| CN109432078B (zh) | 一种化合物在制备预防或治疗电离辐射所致认知障碍药物中的应用 | |
| TR201902517T4 (tr) | 25-hidroksivitamin D3 ile artan eotaksin ile ilişkilendirilen durumların tedavi edilmesi. | |
| CN112135625A (zh) | 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用 | |
| Moghadam et al. | The effect of bacterial composition shifts in the oral microbiota on Alzheimer's disease | |
| ES2995086T3 (en) | Gastrointestinal health composition | |
| ES2953381T3 (es) | Tratamiento y prevención de la enfermedad de Alzheimer (AD) | |
| JP2008533022A5 (enExample) | ||
| CN112805027B (zh) | 一种抗新冠病毒感染的药物与应用 | |
| Kim et al. | Trichuris trichiura infection in North Korean defector resulted in chronic abdominal pain and growth retardation | |
| Cuomo et al. | Almost all irritable bowel syndromes are post-infectious and respond to probiotics: consensus issues | |
| Fernández et al. | Pathological gambling and hypersexuality due to dopaminergic treatment in Parkinson's disease | |
| JP2009522294A5 (enExample) | ||
| Yang et al. | Occurrence of priapism with risperidone–paroxetine combination in an autistic child | |
| Liao et al. | Does young feces make the elderly live better? Application of fecal microbiota transplantation in healthy aging | |
| KR101929682B1 (ko) | 올러유러핀을 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물 | |
| CN101194899A (zh) | 百秋李醇在制备防治老年性痴呆症的药物中的用途 | |
| ES2591354T3 (es) | Tapentadol para su uso en el tratamiento del síndrome de intestino irritable | |
| AU2018368465A1 (en) | Use of cyanobacterial biomass in treating hepatitis B virus infection | |
| CN120732837A (zh) | 黄羽扇豆怀特酮在制备预防或治疗神经退行性疾病药物中的应用 | |
| Nayar et al. | Status of Receipt of ICDS package of services by Under Three children and Pregnant Mothers in District Agra | |
| Akaba et al. | Specific sphingosine kinase 1 inhibitor, SK1-I attenuates neutrophil elastase induced airway inflammation and goblet cell hyperplasia in mice | |
| ES2546897B2 (es) | Uso de la metformina y derivados con actividad como inductores de la fosforilación de AMPK para el tratamiento de la fibromialgia |